Table 3. Clinical characteristics of NET patient samples.

	All patients (n=31)	Pancreatic (n=12)	Non-pancreatic (n=19)
Age: median (range)	62 (42–81)	56 (42–72)	64 (44–82)
Gender
Male	13 (42%)	5 (42%)	8 (42%)
Female	18 (58%)	7 (58%)	11 (58%)
Grade (ENETS)
G1	9 (29%)	3 (25%)	6 (19%)
G2	14 (45%)	5 (42%)	9 (47%)
G3	4 (13%)	3 (25%)	1 (5%)
Unknown	4 (13%)	1 (8%)	3 (16%)
Primary site
Pancreas	12 (39%)	12 (100%)	–
Midgut	18 (58%)	–	18 (95%)
Unknown	1 (3%)	–	1 (5%)
SSTR imaging
Positive	27 (87%)	9 (75%)	18 (95%)
Negative	1 (3%)	1 (8%)	–
Unknown	3 (10%)	2 (17%)	1 (5%)
SA therapy
Yes	19 (61%)	5 (42%)	14 (74%)
No	12 (39%)	7 (58%)	5 (26%)

Abbreviations: ENETS=European Neuroendocrine Tumour Society; NET=neuroendocrine tumours; SA=somatostatin analogues; SSTR=somatostatin receptors.